Brief: Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, And Tolerability Study Of SP-26 For Chronic Pain And Fibromyalgia
11/02/2025 13:02
Feb 11 (Reuters) - Silo Pharma SILO.O :
* SILO PHARMA ANNOUNCES POSITIVE INITIAL PHARMACOKINETIC,
SAFETY,
AND TOLERABILITY STUDY OF SP-26 FOR CHRONIC PAIN AND
FIBROMYALGIA
* SILO PHARMA INC - NO SERIOUS SIDE EFFECTS OBSERVED IN
SP-26
STUDY
* SILO PHARMA INC - FINAL SAFETY AND ABSORPTION DATA
EXPECTED IN
MARCH 2025
Source text: ID:nGNX7qL6FT
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement